NEW YORK, NY
Flatiron Health, a leader in the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, today announced that Dr. Shrujal Baxi, a researcher and medical oncologist formerly at Memorial Sloan Kettering, has joined the company as Medical Director, Research Oncology. In this role, Dr. Baxi will work with Flatiron’s cross-functional teams comprised of engineering, quantitative science, and clinical experts to generate RWE for clinical and regulatory decision making.
At Flatiron, the Research Oncology team oversees day-to-day research planning and execution, which includes input into how data sets are created and used to answer clinically important questions in the field of oncology.
“Given Shrujal’s range of expertise across outcomes research, precision medicine, treatment decision making and clinical care, she will be a tremendous asset to Flatiron’s research initiatives,” said Dr. Neal Meropol, Vice President, Research Oncology. “We are looking forward to leveraging Shrujal’s talents across our research partnerships, including regulatory agencies and academic collaborations.”
To learn more about Flatiron Health, click here or visit our booth #2049 during the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place June 1-5 in Chicago.
Shrujal Baxi, MD, MPH
Shrujal Baxi is a board-certified medical oncologist who currently serves as medical director at Flatiron Health, where she focuses on real-world evidence generation. In addition to active involvement in therapeutic clinical trials, Dr. Baxi has used large national cancer registry data to investigate practice patterns in oncology. In addition, she has published on the non-oncologic outcomes associated with cancer including toxicities of treatment. In response to findings, she investigated systems-level solutions to facilitate delivery of comprehensive survivorship care.
Dr. Baxi simultaneously received her medical degree from the University of Illinois College of Medicine at Chicago and her masters in public health with an emphasis on health policy and administration from the University of Illinois School of Public Health. She then moved to New York City to complete residency at New York University. After serving as a chief resident, Dr. Baxi completed a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center and joined their faculty in 2011, where she specialized in cancers of the head and neck, salivary glands, and thyroid along with non-melanoma cutaneous malignancies.
About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Location:
NEW YORK, NY, May 31, 2018
